Evidence map›Paper›PMID 33106386›Full record

ArticleJournal for immunotherapy of cancer2020

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.

Hampartsoum B Barsoumian, Rishab Ramapriyan, Ahmed I Younes, Mauricio S Caetano, Hari Menon, Nathan I Comeaux, Taylor R Cushman, Jonathan E Schoenhals, Alexandra P Cadena, Timothy P Reilly and 11 more

3 registry-linked trialsAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 142 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06349837 phase1recruitingnot on this mapstarted 2024, after this paper: background citation

Safety and Tolerability of Low Dose Radiotherapy Plus Concurrent Partial Stereotactic Ablative Radiotherapy (Eclipse-RT) and Tislelizumab in Patients With Bulky Tumors

TypeinterventionalSponsorSichuan UniversityRan2024 to 2028Enrolled24ConditionsSolid TumorArmsTislelizumab, Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy
NCT06446726 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of Low-dose Radiation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma

TypeinterventionalSponsorSichuan UniversityRan2024 to 2026Enrolled30ConditionsEsophageal Squamous Cell CarcinomaArmsTislelizumab, Low-dose radiotherapy, Nab-paclitaxel, Cisplatin
NCT06494189 phase1completednot on this mapstarted 2024, after this paper: background citation

A Prospective, Single-arm Clinical Study of Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

TypeinterventionalSponsorWest China HospitalRan2024 to 2025Enrolled9ConditionsHead and Neck CancerArmsTislelizumab, Afatinib, Low dose radiotherapy
3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Correlation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hampartsoum B BarsoumianRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-8209-6119
Rishab RamapriyanRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ahmed I YounesRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1746-4624
Mauricio S CaetanoRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hari MenonRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nathan I ComeauxRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1077-9607
Taylor R CushmanRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jonathan E SchoenhalsRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alexandra P CadenaRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Timothy P ReillyBristol-Myers Squibb Co, New York, New York, USA.
Dawei ChenRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6762-7997
Fatemeh MasrorpourRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ailin LiRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David S HongInvestigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Adi DiabMelanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Quynh-Nhu NguyenRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Isabella GlitzaMelanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4530-7765
Renata FerrarottoThoracic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stephen G ChunRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maria Angelica CortezRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
James WelshRadiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA JWelsh@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundDespite some successes with checkpoint inhibitors for treating cancer, most patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor stroma that impedes the function and entry of effector cells. We devised a new technique of combining immunotherapy with radiotherapy (XRT), more specifically low-dose XRT, to overcome the stroma and maximize systemic outcomes.

methodsWe bilaterally established 344SQ lung adenocarcinoma tumors in 129Sv/Ev mice. Primary and secondary tumors were irradiated with either high-dose or low-dose of XRT with systemic anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte associated protein 4 administration. Survival and tumor growth were monitored for the various groups, and secondary tumors were phenotyped by flow cytometry for immune populations. Tumor growth factor-beta (TGF-β) cytokine levels were assessed locally after low-dose XRT, and specific immune-cell depletion experiments were conducted to identify the major contributors to the observed systemic antitumor effect.

resultsThrough our preclinical and clinical studies, we observed that when tumor burden was high, there was a necessity of combining high-dose XRT to 'prime' T cells at the primary tumor site, with low-dose XRT directed to secondary (metastatic) tumors to 'modulate the stroma'. Low-dose XRT improved the antitumor outcomes of checkpoint inhibitors by favoring M1 macrophage polarization, enhancing natural killer (NK) cell infiltration, and reducing TGF-β levels. Depletion of CD4

conclusionOur data extend the benefits of low-dose XRT to reprogram the tumor environment and improve the infiltration and function of effector immune cells into secondary tumors.

Indexed as

AgedAnimalsFemaleHumansImmunityImmunotherapyMaleMiceNeoplasmsTumor Microenvironmentimmunotherapylung neoplasmsradioimmunotherapyradiotherapytumor microenvironment

Identifiers

PMID33106386
PMCPMC7592253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.